Galapagos, Servier Enter Strategic Alliance for Cancer Therapies
Galapagos NV (GLPG) and Servier of France have entered a strategic alliance to develop new cancer therapies that could potentially result in as much as 260 million euros in milestone payments for Galapagos.
Galapagos will be responsible for the discovery and development of new candidate drugs against the companies’ combined oncology targets. Servier will have an exclusive option to license each small molecule program after the completion of pre-clinical development by Galapagos.
To contact the editor responsible for this story: Andrew Clapham at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.